Ann Taylor Stores upgraded at Credit SuisseANN upgraded to Outperform from Neutral. Expense cuts are source of upside and add downside protection, Credit Suisse said. Price target surged to $31 from $16.
Associated Banc downgraded at UBSASBC was downgraded from Buy to Neutral, UBS said. $16 price target. Company is seeing lower sales.
Associated Banc downgraded at OppenheimerASBC was downgraded from Outperform to Perform, Oppenheimer said. Valuation call, after the company reported disappointing earnings.
Baxter numbers reduced at GoldmanShares of BAX now seen reaching $56, according to Goldman Sachs. Estimates also lowered, because of healthcare reform and slower plasma growth. Neutral rating.
Baxter downgraded at William BlairBAX was downgraded from Outperform to Market Perform, William Blair said. Company lowered its forward earnings guidance.
Cooper Industries upgraded at LongbowCBE was upgraded from Neutral to Buy, Longbow Research said. $60 price target. Company is realizing higher margins and has a strong balance sheet.
Chicos FAS initiated at Credit SuisseCHS coverage assumed at Credit Suisse with a Neutral rating and $16 price target. 2011 and 2012 EPS estimates set at $0.81 and $1.00, respectively.
Columbia Sportswear upgraded at CitiCOLM upgraded to Hold from Sell on better visibility on revenue trends, Citigroup said. Price target surged to $62 from $36. 2010 and 2011 EPS estimates boosted to $2.20 and $3.10, respectively.
Columbia Sportswear numbers upped at GoldmanCOLM estimates were boosted through 2012, Goldman Sachs said. Company is cutting costs and looking at double-digit sales growth. Neutral rating and new $48 price target.
Cepheid upgraded at BairdCPHD was upgraded from Neutral to Outperform, Robert Baird said. $24 price target. Company is seeing strong sales, especially in the clinical area.
Centurytel downgraded at OppenheimerCTL was downgraded from Outperform to Perform, Oppenheimer said. Shares should be range-bound as the company closes on the Q purchase.
Community Health upgraded at WellsCYH was upgraded from Market Perform to Outperform, Wells Fargo said. Medicaid should help drive higher earnings in 2010.
Cosan Limited initiated at Credit SuisseCZZ initiated with an Outperform rating and $17 price target. Significant flexibility to support growth, Credit Suisse said.
Hudson City Bancorp downgraded at BofA/MerrillHCBK downgraded to Underperform from Neutral on margin disappointment, Bank of America/Merrill Lynch said. Price target lowered to $13.
Hershey upgraded at JP MorganHSY upgraded at JP Morgan. Rating raised to Neutral from Underweight. Price target raised to $49.50 from $40.00. 2010 EPS estimates raised to $2.55 from $2.32.
Janus downgraded at GoldmanJNS was downgraded from Buy to Neutral, Goldman Sachs said. $15 price target. Estimates also cut, because of weaker near-term asset flows.
Monster Worldwide upgraded at WellsMWW was upgraded from Underperform to Market Perform, Wells Fargo said. Estimates also boosted, following recent channel checks.
Nokia downgraded at JefferiesNOK was downgraded from Hold to Underperform, Jefferies said. Company posted poor earnings and has limited sales visibility.
Principal Financial upgraded at UBSPFG was upgraded from Sell to Neutral, UBS said. Valuation call, based on a $30 price target.
Qwest upgraded at GoldmanRating on Q was raised from Sell to Neutral, Goldman Sachs said. See limited downside, given the merger with CTL.
Sherwin Williams downgraded at JP MorganSHW downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Price target raised to $81 from $70. 2010 EPS estimates raised to $4.60 from $4.45.
Sirona Dental Systems upgraded at BarclaysSIRO upgraded to Overweight from Equal Weight on good top line visibility and some sense of additional EBITDA upside, Barclays said. Price target lifted to $48 from $41. 2010 and 2011 EPS estimates held at $2.48 and $2.72, respectively.
The Talbots initiated at Credit SuisseTLB coverage assumed with a Neutral rating and $14 price target, Credit Suisse said. 2011 and 2012 EPS estimates set at 77 cents and 98 cents, respectively.
Verizon downgraded at GoldmanVZ was downgraded to Neutral, Goldman Sachs said. $32 price target. Estimates also lowered, given wireline margin pressures.
Western Digital upgraded at BairdWDC was upgraded to Outperform from Neutral, Robert Baird said. $50 price target. Company reported a strong quarter, and guidance should prove to be conservative.
Shares of ABC now seen reaching $35, according to Morgan Stanley. Estimates also increased, given expectations for higher generic sales. Overweight rating.
Alexion Pharma cut from Conviction Buy list at Goldman
ALXN was removed from the Conviction Buy list, Goldman Sachs said. Stock is up 59% over the past year and lacks near-term catalysts. $62 price target.
Alexion Pharma cut from Conviction Buy list at GoldmanALXN was removed from the Conviction Buy list, Goldman Sachs said. Stock is up 59% over the past year and lacks near-term catalysts. $62 price target.
Amazon.com estimates tweaked at CitiAMZN 2010 EPS estimate lowered to $2.89, 2011 raised by a penny to $4.07. Solid Q1 beat with typical conservative guidance, Citigroup said. Maintain Buy rating and $180 price target.
Amazon.com estimates, target increased at GoldmanAMZN estimates were raised through 2012, Goldman Sachs said. Company is seeing accelerating sales growth. Buy rating and new $180 price target.
Autonation estimates, target raised at GoldmanShares of AN now seen reaching $19, according to Goldman Sachs. Estimates also increased, given cost cuts and share buybacks. Sell rating.
American Express target, estimates increased at CitiAXP price target lifted to $55 from $51 on strong 1Q10 numbers. Spending accelerates into March and April, Citigroup said. 2010 and 2011 EPS estimates improved to $2.95 and $3.25, respectively. Buy rating.
American Express numbers boosted at FBRShares of AXP now seen reaching $48, according to FBR Capital Markets. Estimates also upped, because of improving credit quality. Market Perform rating.
Autozone estimates, target raised at GoldmanShares of AZO now seen reaching $185, according to Goldman Sachs. Estimates also increased, following channel checks. Neutral rating.
BB&T estimates, target raised at FBRShares of BBT now seen reaching $30, according to FBR Capital Markets. Estimates also increased, given a wider net interest margin and lower provision expenses. Market Perform rating.
Cheesecake Factory numbers boosted at GoldmanShares of CAKE now seen reaching $32, according to Goldman Sachs. Estimates also upped, given better salesa and margins. Buy rating.
Capital One Financial target, estimate boosted at CitiCOF price target raised to $56 from $49 after positive 1Q10 results. Turing the corner on credit, Citigroup said. 2010 EPS estimate jumped to $2.90, 2011 held at $3.75. Buy rating.
Cypress Semiconductor estimates, target boosted at UBSShares of CY now seen reaching $13.25, according to UBS. Estimates also upped, given designs wins and cost controls. Neutral rating.
Danaher estimates, target raised at GoldmanShares of DHR now seen reaching $100, according to Goldman Sachs. Company is seeing accelerating organic growth. Buy rating.
Dick's Sporting Goods numbers boosted at GoldmanShares of DKS now seen reaching $31, according to Goldman Sachs. Estimates also upped, given better sales expectations. Buy rating.
Exleon estimates, target increased at GoldmanEXC estimates were raised through 2012, Goldman Sachs said. Company should have a positive PECO rate case. Neutral rating and new $48 price target.
Graco estimates, target boosted at GoldmanShares of GGG now seen reaching $35, according to Goldman Sachs. Estimates also upped, given stronger international sales. Sell rating.
Home Depot estimates, target raised at GoldmanShares of HD now seen reaching $38, according to Goldman Sachs. Estimates also increased, because of better home sales and positive lumber pricing. Buy rating.
Hershey estimates, target boosted at GoldmanHSY estimates were upped through 2012, according to Goldman Sachs. Company is seeing higher sales and margins. Sell rating and new $45 price target.
King Pharmaceuticals numbers cut at GoldmanKG estimates were lowered through 2013, Goldman Sachs said. Partner pain drug was rejected by an FDA advisory panel. Sell rating and new $10.50 price target.
Kimberly-Clark target lower, estimates mixed at BarclaysKMB price target sunk to $60 from $65 on valuation. A whole bunch of ifs, Barclays said. 2010 EPS estimate lowered to $4.81, 2011 raised to $5.30. Underweight rating.
L-3 Communications target, estimates boosted at Barclays LLL price target increased to $114 from $97 after 1Q10 beat expectations, Barclays said. 2010 and 2011 EPs estimates raised to $8.20 and $9.15, respectively. Maintain Overweight rating.
Lowe's estimates, target increased at GoldmanLOW estimates were raised through 2012, Goldman Sachs said. Company is seeing higher lumber prices and favorable weather trends. Neutral rating and new $29 price target.
Marriott estimates, target increased at FBRMAR estimates were raised through 2011, FBR Capital Markets said. Company posted a strong quarter and is seeing better demand trends. Market Perform rating and new $38 price target.
Microsoft target, estimates raised at CitiMSFT price target lifted to $37 from $32 after inline 3Q10 results. Leading enterprise indicators improve, Citigroup said. 2010 and 2011 EPS estimates increased to $2.07 and $2.34, respectively. Reiterate Buy rating.
Microsoft estimates, target upped at FBRMSFT estimates were boosted through 2011, FBR Capital Markets said. Company continues to benefit from the new PC upgrade cycle. Market Perform rating and new $31 price target.
Pepsi estimates boosted at UBSPEP estimates were upped through 2011, UBS said. Company is positioned well for the Summer selling season. Buy rating and $76 price target.
PMC-Sierra numbers raised at GoldmanShares of PMCS now seen reaching $11, according to Goldman Sachs. Estimates also increased, as the company is seeing higher sales. Neutral rating.
PNC Financial added to Top Picks list at FBRPNC was added to the Top Picks list, FBR Capital Markets said. $80 price target. Company posted the cleanest quarter amongst its peers.
Pactiv estimates, target lowered at GoldmanShares of PTV now seen reaching $31, according to Goldman Sachs. Estimates also reduced, as the company is facing higher resin costs. Buy rating.
Reynolds American estimates increased at GoldmanRAI estimates were raised through 2012, Goldman Sachs said. Company is seeing higher sales across the board. Sell rating and new $54 price target.
Raymond James added to Top Picks list at FBRRJF was added to the Top Picks list, FBR Capital Markets said. $36 price target. Estimates also boosted, given the company's potential operating leverage. Outperform rating.
Raytheon target, estimates higher at BarclaysRTN price target jumped to $69 from $61 on strong 1Q10 results, Barclays said. 2010 and 2011 EPS estimates set at $5.00 and $5.50, respectively. Reiterate Overweigh rating.
Riverbed Technology numbers boosted at FBRShares of RVBD now seen reaching $29, according to FBR Capital Markets. Estimates also upped, as the company is seeing better deal flow. Market Perform rating.
TCF Financial numbers upped at FBRTCB estimates were boosted through 2011, FBR Capital Markets. Credit environment is stabilizing. Underperform rating and new $16 price target.
Talecris Biotherapeutics numbers lowered at GoldmanTLCR estimates were reduced through 2014, Goldman Sachs said. Company will be hurt by healthcare reform and slower growth in the plasma market. Neutral rating and new $22 price target.
Textron estimates, target increased at GoldmanTXT estimates were raised through 2012, Goldman Sachs said. Company is seeing better industrial margins. Buy rating and new $30 price target.
Union Pacific numbers raised at FBRShares of UNP now seen reaching $88, according to FBR Capital Markets. Estimates also increased, given higher volumes and cost controls. Outperform rating.
Wesco estimates, target increased at FBRWCC estimates were raised through 2011, FBR Capital Markets said. Pricing is helping to drive organic growth. Outperform rating and new $47 price target.
Watsco estimates, target boosted at Morgan StanleyShares of WSO now seen reaching $69, according to Morgan Stanley. Estimates also upped, given the company's new sales guidance. Overweight rating.
